ANN ARBOR, Mich., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) ("Zomedica" or the "Company"), a veterinary pharmaceutical and health care solutions company, today announced that the NYSE American has approved the Company’s common shares for listing. Trading of the common shares on the NYSE American will not commence until after Zomedica’s Registration Statement on Form S-1 is declared effective by the U.S. Securities and Exchange Commission (the “SEC”). No assurance can be given that the Registration Statement will be declared effective by the SEC or as to the timing thereof.
With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica is developing a diversified portfolio to include diagnostics, devices, innovative drugs, and drug-delivery technologies. With a team comprised of clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Investor Relations Contact
Shameze Rampertab, CPA, CA
PCG Advisory Group
Kirin Smith, COO
Zomedica Pharmaceuticals Corp.